Anti-pan-AKT antibody (ab18785)
- Product nameAnti-pan-AKT antibodySee all pan-AKT primary antibodies ...
- DescriptionRabbit polyclonal to pan-AKT
- Specificityab18785 detects Akt1, Akt2 and Akt3.
- Tested applicationsIHC-Fr, WB, IP more details
- Species reactivityReacts with: Mouse, Rat, Cow, Human
Synthetic peptide corresponding to residues surrounding aa 80 of Akt (N terminal)(Human) (Peptide available as ab53312.)
- Positive control
- mouse small intestine tissue lysate
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, 1% BSA, PBS, pH 7.2
- Concentration information loading...
- PurityImmunogen affinity purified
- Clonality Polyclonal
Our Abpromise guarantee covers the use of ab18785 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IP: Use at a concentration of 10 - 40 µg/ml.
WB: Use at a concentration of 1 - 2 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 56 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionPlays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.
- Tissue specificityExpressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.
- Involvement in diseaseDefects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).
- Sequence similaritiesBelongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 PH domain.
Contains 1 protein kinase domain.
- DomainBinding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
The AGC-kinase C-terminal mediates interaction with THEM4.
modificationsPhosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells.
Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.
- Cellular localizationCytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.
- AKT 1 antibody
- AKT 2 antibody
- AKT 3 antibody
- AKT1 antibody
- AKT1_HUMAN antibody
- AKT2 antibody
- AKT3 antibody
- C AKT antibody
- CAKT antibody
- DKFZP434N0250 antibody
- MGC99656 antibody
- Murine thymoma viral (v akt) homolog 2 antibody
- murine thymoma viral (v akt) oncogene homolog 1 antibody
- Murine thymoma viral (vakt) oncogene homolog 1 antibody
- PKB Akt antibody
- PKB alpha antibody
- PKB antibody
- PKB beta antibody
- PKBalpha antibody
- PKBBETA antibody
- PKBG antibody
- PRKBA antibody
- PRKBB antibody
- PRKBG antibody
- Protein kinase Akt 2 antibody
- Protein kinase Akt 3 antibody
- Protein kinase B antibody
- Protein kinase B beta antibody
- Protein kinase B gamma antibody
- Proto-oncogene c-Akt antibody
- RAC alpha antibody
- RAC alpha serine/threonine protein kinase antibody
- RAC antibody
- RAC beta antibody
- RAC beta serine/threonine protein kinase antibody
- RAC gamma antibody
- RAC gamma serine/threonine protein kinase antibody
- RAC PK alpha antibody
- RAC PK beta antibody
- RAC PK gamma antibody
- Rac protein kinase alpha antibody
- Rac protein kinase beta antibody
- RAC Serine/Threonine Protein Kinase antibody
- RAC-alpha serine/threonine-protein kinase antibody
- RAC-PK-alpha antibody
- Serine threonine protein kinase Akt 3 antibody
- STK 2 antibody
- STK2 antibody
- V AKT Murine Thymoma Viral Oncogene Homolog 1 antibody
- v akt murine thymoma viral oncogene homolog 2 antibody
- v akt murine thymoma viral oncogene homolog 3 antibody
- VAKT Murine Thymona Viral Oncogene 1 antibody
Anti-pan-AKT antibody images
Anti-pan-AKT antibody (ab18785) + Akt expression in NIH3T3 cell lysate
Predicted band size : 56 kDa
Observed band size : 56 kDa
ICC/IF image of ab18785 stained HepG2 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab18785, ug/ml) overnight at +4oC. The secondary antibody (green)was Alexa Fluor© 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor© 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43uM.
References for Anti-pan-AKT antibody (ab18785)
This product has been referenced in:
- Hartz AM et al. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther 334:467-76 (2010). WB ; Rat . Read more (PubMed: 20460386) »